Plus Therapeutics, Inc. announced on March 20, 2025, that the U.S. Food and Drug Administration (FDA) has conditionally accepted REYOBIQ™ as the new proprietary name for its lead therapeutic candidate. REYOBIQ™ is rhenium Re 186 obisbemeda, currently under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM).
The establishment of the REYOBIQ™ brand is an important part of preparing for commercialization. This branding effort aims to enable investigators, investors, and potential patients to connect with the rhenium-based radiotherapeutic beyond its chemical identity.
All future communications regarding the USAN-adopted and INN-recommended generic name will now utilize the proprietary name REYOBIQ™. The company anticipates this will foster stronger stakeholder engagement and reinforce the progress in developing targeted radiotherapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.